The Cost of Innovation: The Link Between Patents and Drug Prices
Channel: R Street Institute
Date: 2018-06-11

R Street Institute is a nonprofit, nonpartisan, public policy research organization. Our mission is to engage in policy research and outreach to promote free markets and limited, effective government.

We believe free markets work better than the alternatives. We also recognize that the legislative process calls for practical responses to current problems. To that end, our motto is “Free markets. Real solutions.”

We offer research and analysis that advance the goals of a more market-oriented society and an effective, efficient government, with the full realization that progress on the ground tends to be made one inch at a time. In other words, we look for free-market victories on the margin.

Learn more at https://www.rstreet.org/
Follow us on Twitter at @RSI
Find us on Facebook at https://www.facebook.com/RStreetInstitute/
Find us on LinkedIn at https://www.linkedin.com/company/r-street-institute/ Recent polling shows that 8 in 10 Americans believe that drug prices are “unreasonable,” and a majority think that taking action to lower prescription drug prices should be the top priority for Congress. The link between patents and high drug prices is gaining attention in policy debates in the U.S, as it looks for solutions to tackle the drug pricing problem.